ArticleNature communications2021
Cell-specific and divergent roles of the CD40L-CD40 axis in atherosclerotic vascular disease.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 82 citations in OpenAlex.
- Platelets as non-canonical immune regulatory nodes: orchestrating T cell dysfunction and immunotherapy resistance in cancer.Apoptosis : an international journal on programmed cell death · 2026Review
- Platelets as non-canonical immune regulatory nodes: orchestrating T cell dysfunction and immunotherapy resistance in cancer.Apoptosis : an international journal on programmed cell death · 2026Review
- Rare-Earth Nanomaterials for Advanced Theranostics of Atherosclerosis.Chemical & biomedical imaging · 2026Review
- Dendritic Cells in the Immunoregulation of Myocardial Infarction: Mechanisms and Therapeutic Strategies.Cardiovascular drugs and therapy · 2026Review
- Integrative Omics Analysis Reveals a CD206Barrier immunity · 2026Article
- Senolytic Changes in Murine Arteriovenous Fistulas with CKD.Kidney360 · 2026Article
- Germanane Quantum Dots Promote Metabolic Reprogramming of Immune Cells Toward Regulatory T Cells and Suppress Inflammation In Vitro and In Vivo.Advanced functional materials · 2026Article
- Molecular basis of coronary artery disease-malignancy comorbidity: inflammation, immunometabolism, thrombosis, and cardio-oncology translation.Frontiers in immunology · 2026Review
- PCBP2 Regulates p16Aging cell · 2025Article
- CD40-CD154 Interactions Induced Progressive Neurodegeneration in Acute Ocular Hypertension Mice.Investigative ophthalmology & visual science · 2025Article
- CD40-CD40L: a milestone in the recognition of atherosclerosis as an immune disease.Nature reviews. Cardiology · 2025Article
- Immunoinformatics study of CD40 ligand-targeting vaccine constructs: a novel immunotherapeutic approach.Osong public health and research perspectives · 2025Article
- Cancer-Related Immune Therapies: Bidirectional Implications From Cardiotoxicity to Emerging Cardiovascular Therapeutics: JACC CardioOncology State-of-the-Art Review.JACC. CardioOncology · 2025Review
- A programmable platelet theranostic platform for adaptive multi-stage delivery and synergistic immunotherapy in atherosclerosis.Nature communications · 2025Article
- Bioengineering Platelets Presenting PD-L1, Galectin-9 and BTLA to Ameliorate Type 1 Diabetes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Immunological Features and Potential Biomarkers of Systemic Sclerosis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis.The clinical respiratory journal · 2025Article
- CD40-TRAF6 inhibition suppresses cardiovascular inflammation, oxidative stress and functional complications in a mouse model of arterial hypertension.Redox biology · 2025Article
- TNF superfamily molecules in atherosclerosis: mechanistic insights and therapeutic translation.Frontiers in immunology · 2025Review
- Molecular mechanisms and therapeutic progress in atherosclerosis: bridging immune inflammation and precision medicine.Frontiers in immunology · 2025Review
- Dengue infection changes the expressions of CD154 and CD148 in human platelets.Virus research · 2025Article
Corrections and comments
- Commented on by
Authors and funding
25 authors at 8 institutions in 3 countries.
Michael Lacy *Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.ORCID 0000-0001-5944-582X
Christina Bürger *Institute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Annelie Shami *Department of Clinical Sciences Malmö, Lund University, Clinical Research Center, Malmö, Sweden.
Maiwand AhmadseiInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Holger WinkelsInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Katrin NitzInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Claudia M van TielDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Tom T P SeijkensDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Pascal J H KustersDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Ela KarshovkaInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Koen H M PrangeDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Yuting WuInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Sanne L N BrounsDepartment of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
Sigrid UnterlugauerInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Marijke J E KuijpersDepartment of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
Myrthe E ReicheDepartment of Medical Biochemistry, Amsterdam Cardiovascular Sciences (ACS), Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Sabine SteffensInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Andreas EdsfeldtDepartment of Clinical Sciences Malmö, Lund University, Clinical Research Center, Malmö, Sweden.
Remco T A MegensInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.ORCID 0000-0001-9871-6696
Johan W M HeemskerkDepartment of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.ORCID 0000-0002-2848-5121
Isabel GoncalvesDepartment of Clinical Sciences Malmö, Lund University, Clinical Research Center, Malmö, Sweden.
Christian WeberInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany.
Norbert GerdesInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany. Norbert.Gerdes@med.uni-duesseldorf.de.ORCID 0000-0002-4546-7208
Dorothee AtzlerInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany. dorothee.atzler@med.uni-muenchen.de.ORCID 0000-0002-6551-1544
Esther LutgensInstitute for Cardiovascular Prevention (IPEK), Ludwig-Maximilians-Universität, Munich, Germany. Esther.Lutgens@med.uni-muenchen.de.ORCID 0000-0002-2609-5744
Amsterdam University Medical Centers · NLGerman Centre for Cardiovascular Research · DELudwig-Maximilians-Universität München · DEMaastricht University · NLLund University · SEDüsseldorf University Hospital · DETUM Klinikum · DEUniversity Hospital Cologne · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis is a major underlying cause of cardiovascular disease. Previous studies showed that inhibition of the co-stimulatory CD40 ligand (CD40L)-CD40 signaling axis profoundly attenuates atherosclerosis. As CD40L exerts multiple functions depending on the cell-cell interactions involved, we sought to investigate the function of the most relevant CD40L-expressing cell types in atherosclerosis: T cells and platelets. Atherosclerosis-prone mice with a CD40L-deficiency in CD4
Indexed as
AnimalsAtherosclerosisBlood PlateletsCardiovascular DiseasesCD40 AntigensCD40 LigandCD4-Positive T-LymphocytesDendritic CellsInterferon-gammaMiceMice, KnockoutMyocytes, Smooth MusclePlaque, AtheroscleroticSignal TransductionThrombosisCD40 AntigensCD40 LigandIFNG protein, mouseInterferon-gamma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.